The IL17RB Knockout PaTu 8988t Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the PaTu 8988t pancreatic adenocarcinoma cell line, designed for loss-of-function studies of the IL17RB gene. This polyclonal knockout cell product provides a heterogeneous pool of cells with targeted disruption of IL17RB, enabling investigation of gene function without clonal selection artifacts.
The host cell line, PaTu 8988t, is a well-characterized human pancreatic ductal adenocarcinoma (PDAC) cell line isolated from a liver metastasis. As an epithelial cancer model, it retains key oncogenic features of metastatic pancreatic cancer, making it suitable for studying tumor-intrinsic signaling pathways and their impact on proliferation, migration, and inflammatory interactions within the tumor microenvironment.
The IL17RB gene encodes the receptor for interleukin-25 (IL-25, also known as IL-17E) and IL-17B. Upon ligand binding, IL17RB heterodimerizes with IL-17RA, recruiting the adaptor protein ACT1 (TRAF3IP2) and activating downstream TRAF6-dependent pathways. TRAF6-mediated K63-linked ubiquitination events activate the TAK1 kinase complex, which phosphorylates the I??B kinase (IKK) complex, resulting in NF-??B activation and nuclear translocation. Concurrently, the MAPK pathway is stimulated through phosphorylation of ERK, leading to AP-1-mediated transcription. This signaling cascade drives expression of pro-inflammatory mediators including IL-6, IL-8, and CXCL1. Through these mechanisms, IL17RB governs Th2-type allergic inflammation and contributes to host defense responses.
Disruption of IL17RB in PaTu 8988t cells offers a powerful tool to dissect the contribution of IL-25/IL-17RB signaling to pancreatic cancer cell-intrinsic properties. This model enables elucidation of how this receptor axis modulates NF-??B-mediated cytokine production and MAPK-driven proliferative responses, processes implicated in the aggressive metastatic phenotype of pancreatic cancer.
Researchers can employ the IL17RB Knockout PaTu 8988t Polyclonal Cells to dissect IL-25/IL-17RB-driven signaling pathways in pancreatic cancer, including analyses of NF-??B and MAPK activation by western blotting, quantification of cytokine transcripts via RT-qPCR, and functional assays such as cell proliferation and migration. This knockout model also supports drug target validation studies and inflammatory disease modeling where IL-17RB-mediated responses are implicated. For more information or to inquire about custom projects, please contact Ascent Research.
